SCHEMBL9108971

SCHEMBL9108971

C=CCCC(=O)Nc1cc(-c2nc(-c3nnc[nH]3)c(-c3ccccc3Cl)o2)ccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.36
NPC1 O15118 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK14 Q16539 6/20 0.34
NR4A2 P43354 2/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
EGFR P00533 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK10 P53779 1/20 0.33
AURKA O14965 1/20 0.33
GSK3A P49840 1/20 0.33
CDC7 O00311 1/20 0.32
DAPK3 O43293 1/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32
PRKACA P17612 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9104647 0.90 CDC7 (0.42) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL626224 0.88 JAK2 (0.42) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL9109816 0.87 MAPK8 (0.48) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL9108071 0.86 MAPK14 (0.46) GSK3BRAB9AMAPK14NR4A2SMN1; SMN2
SCHEMBL9104044 0.85 MEN1 (0.40) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL9110056 0.85 MAPK14 (0.41) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL9105551 0.84 MAPK14 (0.41) GSK3BRAB9AMAPK14MAPK10GSK3A
SCHEMBL9890572 0.83 GSK3B (0.49) GSK3BMAPK14GSK3A
SCHEMBL9106751 0.83 GSK3B (0.37) GSK3BNPC1KDM4EMAPTRAB9A
SCHEMBL16167589 0.79 CDC7 (0.43) GSK3BNPC1KDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 GSK3B 734/4885NPC1 91/4885KDM4E 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.